Key Insights

Highlights

Success Rate

72% trial completion

Published Results

45 trials with published results (11%)

Research Maturity

133 completed trials (33% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.8%

51 terminated out of 399 trials

Success Rate

72.3%

-14.2% vs benchmark

Late-Stage Pipeline

5%

19 trials in Phase 3/4

Results Transparency

34%

45 of 133 completed with results

Key Signals

45 with results72% success51 terminated

Data Visualizations

Phase Distribution

291Total
Not Applicable (64)
Early P 1 (1)
P 1 (87)
P 2 (120)
P 3 (13)
P 4 (6)

Trial Status

Completed133
Recruiting86
Unknown64
Terminated51
Active Not Recruiting24
Not Yet Recruiting20

Trial Success Rate

72.3%

Benchmark: 86.5%

Based on 133 completed trials

Clinical Trials (399)

Showing 20 of 20 trials
NCT02626312Phase 1Active Not RecruitingPrimary

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT05967182Phase 2RecruitingPrimary

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT04145141Active Not Recruiting

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT02872831Not ApplicableWithdrawn

Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle

NCT05461430Completed

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT01915225Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

NCT04645160Phase 1RecruitingPrimary

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT06971848Not ApplicableNot Yet Recruiting

Evaluation of Skin Tests in Biotherapy Allergies

NCT06503146Phase 2Recruiting

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT07260175Phase 2RecruitingPrimary

Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

NCT07213791Phase 1Recruiting

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

NCT07486713Phase 4Recruiting

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

NCT05411133Phase 1Completed

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

NCT06648057Recruiting

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

NCT07478523Phase 2Not Yet RecruitingPrimary

FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers

NCT06474091Enrolling By InvitationPrimary

Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)

NCT06381648CompletedPrimary

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

NCT04792463Recruiting

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Scroll to load more

Research Network

Activity Timeline